Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study

  • Federico Caobelli
  • Pierpaolo AlongiEmail author
  • Laura Evangelista
  • Maria Picchio
  • Giorgio Saladini
  • Marco Rensi
  • Onelio Geatti
  • Angelo Castello
  • Iashar Laghai
  • Cristina E. Popescu
  • Carlotta Dolci
  • Cinzia Crivellaro
  • Silvia Seghezzi
  • Margarita Kirienko
  • Vincenzo De Biasi
  • Fabrizio Cocciolillo
  • Natale Quartuccio
  • Young AIMN Working Group
Original Article



Ovarian cancer is the eighth most common malignancy among women and has a high mortality rate. Prognostic factors able to drive an effective therapy are essential. 18F-Fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has been investigated in patients with epithelial ovarian cancer and showed promise in diagnosing, staging, detecting recurrent lesions and monitoring treatment response. Conversely, its prognostic role remains unclear. We aimed at assessing the prognostic value of 18F-FDG PET/CT performed in the restaging process in a multicentre study.


We evaluated 168 patients affected by ovarian carcinoma, who underwent a restaging 18F-FDG PET/CT. The presence of local recurrences, lymph node involvement and distant metastasis was recorded as well as lesion dimensions, maximum and mean standardized uptake values (SUVmax and SUVmean, respectively). Progression-free survival (PFS) and overall survival (OS) at 3 and 4 years were computed by using Kaplan-Meier curves. Increased odds ratio was assessed using Cox regression analysis testing all lesion parameters measured by PET/CT.


PFS was significantly longer in patients with a negative than a positive restaging PET/CT study (3- and 4-year PFS 64 and 53 % vs 23 and 12 %, respectively; p < 0.001). Similarly, a negative study was associated with a significantly higher OS rate after 4 years of follow-up (67 vs 25 % in negative and positive groups, respectively; p < 0.001). Lymph node or distant involvement were also independently associated with an increased risk of disease progression [hazard ratio (HR) 1.6 and 2.2, respectively; p = 0.003]. Moreover, PET/CT showed an incremental prognostic value compared to the International Federation of Gynecology and Obstetrics (FIGO) staging system. In the analysis of patient subsets, individuals with the same FIGO stage I–II but with negative PET had a significantly better 4-year OS than patients with low FIGO stage but positive PET. This implies that patients with the same FIGO stage can be further prognostically stratified using PET (p = 0.01). At receiver-operating characteristic (ROC) analysis, no thresholds for semiquantitative parameters were predictive of a worse outcome.


18F-FDG PET/CT has an important prognostic value in assessing the risk of disease progression and mortality rate. An efficacious therapy planning might therefore effectively rely on 18F-FDG PET/CT findings. Semiquantitative data were not proven to be an effective tool to predict disease progression.


Ovarian carcinoma 18F-FDG PET/CT Prognostic value FIGO staging system Restaging 



We would like to thank all the institutions and their co-workers who actively participated in our multicentre study for their invaluable help. We also thank Dr. James T. Thackeray for language editing and thorough revision of the manuscript.

Compliance with ethical standards

Conflicts of interest


Financial support

The authors disclose that they did not receive any personal or financial support for this multicentre study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011;61:183–203.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403.PubMedCrossRefGoogle Scholar
  3. 3.
    Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Zytoon AA, Murakami K, Eid H, El-Gammal M. High impact of FDG-PET/CT in diagnostic strategies for ovarian cancer. Acta Radiol 2013;54:340–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer 2013;23:598–607.PubMedCrossRefGoogle Scholar
  6. 6.
    Konishi H, Takehara K, Kojima A, Okame S, Yamamoto Y, Shiroyama Y, et al. Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. Int J Gynecol Cancer 2014;24:1190–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Risum S, Loft A, Engelholm SA, Høgdall E, Berthelsen AK, Nedergaard L, et al. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer. Int J Gynecol Cancer 2012;22:1163–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, et al. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? Gynecol Oncol 2010;116:395–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kurosaki H, Oriuchi N, Okazaki A, Tamaki T, Uki A, Izuta M, et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med 2006;20:171–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakamura K, Hongo A, Kodama J, Hiramatsu Y. The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer. Acta Med Okayama 2012;66:53–60.PubMedGoogle Scholar
  11. 11.
    Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol 2012;19:1966–72.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee JW, Cho A, Lee JH, Yun M, Lee JD, Kim YT, et al. The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET/CT in the prognosis of epithelial ovarian cancer. Eur J Nucl Med Mol Imaging 2014;41:1898–906.PubMedCrossRefGoogle Scholar
  13. 13.
    Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kim HW, Won KS, Zeon SK, Ahn BC, Gayed IW. Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PET/CT. Clin Nucl Med 2013;38:93–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D. The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 2009;50 Suppl 1:64S–73.Google Scholar
  16. 16.
    Hebel CB, Behrendt FF, Heinzel A, Krohn T, Mottaghy FM, Bauerschlag DO, et al. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer. Eur J Radiol 2014;83:463–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Kim CY, Jeong SY, Chong GO, Son SH, Jung JH, Kim DH, et al. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. Gynecol Oncol 2015;136:498–504. doi: 10.1016/j.ygyno.2014.12.032.PubMedCrossRefGoogle Scholar
  18. 18.
    Nishiyama Y, Yamamoto Y, Kanenishi K, Ohno M, Hata T, Kushida Y, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging 2008;35:287–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Liao S, Lan X, Cao G, Yuan H, Zhang Y. Prognostic predictive value of total lesion glycolysis from 18F-FDG PET/CT in post-surgical patients with epithelial ovarian cancer. Clin Nucl Med 2013;38:715–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Boers-Sonderen MJ, de Geus-Oei LF, Desar IM, van der Graaf WT, Oyen WJ, Ottevanger PB, et al. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Target Oncol 2014;9:339–47.PubMedCrossRefGoogle Scholar
  21. 21.
    Torizuka T, Kanno T, Futatsubashi M, Okada H, Yoshikawa E, Nakamura F, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med 2003;44:1051–6.PubMedGoogle Scholar
  22. 22.
    Tsujikawa T, Yoshida Y, Mori T, Kuokawa T, Fujibayashi Y, Kotsuji F, et al. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17-beta-estradiol and 18F fluorodeoxyglucose PET—initial experience. Radiology 2008;248:599–605.PubMedCrossRefGoogle Scholar
  23. 23.
    Tsuyoshi H, Morishita F, Orisaka M, Okazawa H, Yoshida Y. 18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients. Clin Nucl Med 2013;38:560–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Risum S, Høgdall C, Markova E, Berthelsen AK, Loft A, Jensen F, et al. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer 2009;19:600–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Takekuma M, Maeda M, Ozawa T, Yasumi K, Torizuka T. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol 2005;10(3):177–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen YM, Chen T, Zee CS, Shi YP, Wan LR, Tong LJ. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center. Nucl Med Commun 2014;35:347–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31–46.PubMedCrossRefGoogle Scholar
  28. 28.
    Karantanis D, Allen-Auerbach M, Czernin J. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012;37:49–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Murakami M, Miyamoto T, Iida T, Tsukada H, Watanabe M, Shida M, et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16 Suppl 1:99–107.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Federico Caobelli
    • 1
  • Pierpaolo Alongi
    • 2
    • 3
    Email author
  • Laura Evangelista
    • 4
  • Maria Picchio
    • 3
  • Giorgio Saladini
    • 4
  • Marco Rensi
    • 5
  • Onelio Geatti
    • 5
  • Angelo Castello
    • 6
  • Iashar Laghai
    • 6
  • Cristina E. Popescu
    • 7
  • Carlotta Dolci
    • 8
  • Cinzia Crivellaro
    • 8
  • Silvia Seghezzi
    • 9
  • Margarita Kirienko
    • 2
  • Vincenzo De Biasi
    • 10
  • Fabrizio Cocciolillo
    • 11
  • Natale Quartuccio
    • 12
  • Young AIMN Working Group
    • 13
  1. 1.Klinik für NuklearmedizinMedizinische Hochschule HannoverHanoverGermany
  2. 2.Nuclear Medicine UnitUniversity of Milano-BicoccaMilanItaly
  3. 3.Nuclear Medicine DepartmentIRCSS San Raffaele Scientific InstituteMilanItaly
  4. 4.Radiotherapy and Nuclear Medicine UnitVeneto Institute of Oncology IOV – IRCCSPaduaItaly
  5. 5.Nuclear Medicine DepartmentHospital of UdineUdineItaly
  6. 6.Nuclear Medicine DepartmentUniversity of FlorenceFlorenceItaly
  7. 7.Nuclear Medicine DepartmentNiguarda Ca’ Granda HospitalMilanItaly
  8. 8.Nuclear Medicine Department; San Gerardo Hospital, Tecnomed FoundationUniversity of Milan-BicoccaMilanItaly
  9. 9.Nuclear Medicine DepartmentHospital of TreviglioTreviglioItaly
  10. 10.Nuclear Medicine Department, Arcispedale Santa Maria NuovaReggio EmiliaItaly
  11. 11.Nuclear Medicine DepartmentCatholic University of the Sacred HeartRomeItaly
  12. 12.Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphological and Functional ImagesUniversity of MessinaMessinaItaly
  13. 13.Executive Committee of the Italian Association of Nuclear Medicine – Youth SectionMilanItaly

Personalised recommendations